Modern Healthcare8d
Teladoc, LifeMD partner with Eli Lilly on GLP-1s
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
pharmaphorum6d
CHMP backs Lilly’s Baqsimi as non-injectable for severe low blood sugar
Lilly’s new product was approved by the ... Both products are priced at a similar level to the glucagon injection kits available on the market, with a list price of $280 per dose, and in the ...
Hosted on MSN22d
Lilly's next obesity drug serves up dramatic weight loss -- and side effects - report
Unlike Lilly's currently marketed obesity treatment Zepbound (tirzepatide), which is given as an injection once a week, retatrutide is a triple-acting GIP/GLP-1/glucagon receptor agonist that is ...
pharmaphorum5y
Xeris’ severe low blood sugar pen gets FDA approval
Towards the end of July, the FDA approved Eli Lilly’s intranasal formulation ... many people may have been hesitant to use conventional glucagon kits because the complex preparation felt ...